PD-L1 + 4-1BB (CD137)

Assets acting on this target.

Class
PD-L1/4-1BB bispecific antibody (opamtistomig)
Pathway
PD-L1 checkpoint blockade combined with 4-1BB costimulatory agonism to enhance anti-tumor T-cell activity

PD-L1 is a protein expressed on tumor cells and some immune cells that normally engages the receptor PD-1 on T cells, delivering an inhibitory signal that dampens T-cell attack on tissue, including tumors that hijack this checkpoint to evade immune destruction. 4-1BB (CD137) is a costimulatory receptor found on activated T cells and other immune cells; when engaged, it reinforces T-cell survival, proliferation, and cytotoxic function. A bispecific antibody that targets both aims to combine two complementary actions: blocking the inhibitory PD-L1/PD-1 checkpoint while simultaneously delivering a costimulatory boost through 4-1BB. Because 4-1BB agonists given alone can activate immune cells throughout the body, pairing 4-1BB engagement with a PD-L1-binding arm is intended to concentrate that activation at sites where PD-L1 is abundant, typically the tumor and its surrounding tissue. This dual mechanism is broadly relevant to solid tumor types in which checkpoint blockade alone produces limited or short-lived responses, with the rationale that adding localized costimulation may generate a more durable and potent anti-tumor T-cell response than blocking the checkpoint alone.

By indication

Related mechanisms

PD-L1 + 4-1BB (CD137) drugs compared

2 drugs, stage by indication
2 drugs acting on PD-L1 + 4-1BB (CD137): developer, modality, furthest stage and stage in each indication. Furthest stage first.
DrugDeveloperModalityFurthest stageStage by indication
OpamtistomigNanjing Leads Biolabs Co.,Ltdmonoclonal antibodyPhase 2Phase 2 in Non-Small Cell Lung Cancer
AP203AP Biosciences Inc.bispecific antibodyPhase 1/2Phase 1/2 in Non-Small Cell Lung Cancer

← all mechanisms